Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
Dublin, Jan. 17, 2025 (GLOBE NEWSWIRE) -- The "Innovation Insights: B-cell Depletion" report has been added to ResearchAndMarkets.com's offering.
Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma
01:00am, Monday, 13'th Jan 2025
The VENTANA Kappa and Lambda Dual ISH mRNA Probe Cocktail assay is the first clinically approved in-situ hybridisation (ISH) test with the sensitivity to assess the full spectrum of B-cell lymphoma su
Roche's momentum in digital pathology continues with FDA clearance on its high-volume slide scanner
01:00am, Thursday, 09'th Jan 2025
The VENTANA DP 600 slide scanner, part of Roche's Digital Pathology Dx system, is now cleared by the FDA to aid in clinical diagnosis, enabling pathologists to diagnose patients using digital images.
Roche set to finalise $1.5bn Poseida Therapeutics takeover
06:32am, Wednesday, 08'th Jan 2025
Swiss healthcare firm Roche has said its US$1.5 billion takeover of US biopharmaceutical company Poseida Therapeutics will be completed on Wednesday. Roche on Wednesday said it had been accepted for p
Roche to complete acquisition of U.S. biopharma company Poseida
01:35am, Wednesday, 08'th Jan 2025
Roche on Wednesday said it planned to complete its purchase of U.S. biopharmaceutical company Poseida Therapeutics via its subsidiary Blue Giant Acquisition Corp.
Roche purchases shares in tender offer for Poseida Therapeutics, Inc.
01:10am, Wednesday, 08'th Jan 2025
Basel, 8 January 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche's wholly owned subsidiary Blue Giant Acquisition Corp. has accepted for payment all shares validly tendered and
Roche Vabysmo Sales Surpassed USD 4 Billion In 2024
11:19am, Tuesday, 07'th Jan 2025
Vabysmo Sales Accounts For More Than 35% Of Global Bispecific Antibodies Market Says Kuick Research Vabysmo Sales Accounts For More Than 35% Of Global Bispecific Antibodies Market Says Kuick Research
Roche Executing Commercially, But R&D Productivity Remains A Work In Progress
04:56am, Saturday, 04'th Jan 2025
Roche Executing Commercially, But R&D Productivity Remains A Work In Progress
Innovent Enters into Exclusive Global License Agreement with Roche for Novel DLL3 Antibody Drug Conjugate
06:30pm, Wednesday, 01'st Jan 2025
SAN FRANCISCO and SUZHOU, China , Jan. 1, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commerciali
Roche has no plans for job cuts and business is healthy, CEO says
12:25pm, Sunday, 29'th Dec 2024
Swiss pharmaceutical company Roche is not planning job cuts and its business is healthy, CEO Thomas Schinecker was quoted as saying by a Swiss newspaper on Sunday.
Roche's Prasinezumab Misses Goal in Parkinson's Disease Study
02:25pm, Thursday, 19'th Dec 2024
The phase IIb PADOVA study, evaluating Roche's prasinezumab in people with early-stage Parkinson's disease, misses the primary endpoint.
Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study
08:33am, Thursday, 19'th Dec 2024
An experimental Parkinson's drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
Bank of Japan faces more pressure to raise rates in 2025, says David Roche
04:19am, Thursday, 19'th Dec 2024
David Roche, strategist at Quantum Strategy, discusses the Bank of Japan's latest interest rate decision and its outlook in 2025.
DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena today announced results from PADOVA study conducted by partner Roche investigating prasinezumab in early-stage Parkinson's disease.
Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease
01:00am, Thursday, 19'th Dec 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in
